Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Seventy-three healthy participants (control group; n=45) and treatment-resistant depression patients (patient group; n=28) were randomized to receive a single oral liquid dose of 1mL/kg of ayahuasca or placebo in this randomized, double-blinded, placebo-controlled trial investigating the effects of ayahuasca on blood inflammatory biomarkers, as well as the correlation of these biomarkers with depressive symptoms. The primary outcome of interest was depression severity as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Other outcome measures include the quantification of plasma C-reactive protein (CRP) and serum interleukin 6 (IL-6), cortisol, brain-derived neurotrophic factor (BDNF), glutamic oxalacetic transaminase (GOT), and glutamic pyruvic transaminase (GPT) inflammatory biomarker levels which were quantified from blood samples. At baseline, patients showed higher CRP levels than healthy controls and a significant negative correlation was found between these elevated levels of CRP and serum cortisol. At 2 days post-treatment, patients treated with ayahuasca showed a significant reduction of CRP levels, which was also found to be significantly correlated with lower depressive symptoms. No other significant results were found for other biomarkers.